Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 69, Issue 5, 2000, Pages 664-667

  Saez Valero J ^a   Barquero, M S ^b   Marcos, A ^b   McLean, C A ^a   Small, D H ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Diagnosis; Glycosylation

Indexed keywords

ACETYLCHOLINESTERASE; BIOCHEMICAL MARKER; ISOPROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ENZYME GLYCOSYLATION; FEMALE; HUMAN; HUMAN TISSUE; LUMBAR SPINE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033784130     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.69.5.664     Document Type: Article

References (17)

1. Pfeffer RI, Afifi AA, Chance JM. Prevalence of Alzheimer's disease in a retirement community. Am J Epidemiol 1987;125:420-36.
2. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
3. Growdon JH. To tap or not to tap: cerebrospinal fluid biomarkers of Alzheimer's disease. Ann Neurol 1998;44:6-7.
4. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998; 44:17-26.
5. Massoulié J, Bon S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Annu Rev Neurosci 1982;5:57-106.
6. Taylor P, Radic Z. The cholinesterases, from genes to proteins. Annu Rev Pharmacol 1994;34:281-320.
7. Small DH, Michaelson S, Sberna G. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem Int 1996;28: 453-83.
8. Friede RL. Enzyme histochemical studies of senile plaques. J Neuropathol Exp Neurol 1965;24:477-91.
9. Mesulam MM, Geula C, Moran MA. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann Neurol 1987;22:683-91.
10. Sáez-Valero J, Sberna G, McLean CA, et al. Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease. Lancet 1997;350:929.
11. Sáez-Valero J, Sberna G, McLean CA, et al. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J Neurochem 1999;72:1600-8.
12. Sberna G, Sáez-Valero J, Li QX, et al. Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the β-amyloid protein precursor of Alzheimer's disease. J Neurochem 1998;71:723-31.
13. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72.
14. Sáez-Valero J, Tornel PL, Muñoz-Delgado E, et al. Amphiphilic and hydrophilic forms of acetyl- and butyryl-cholinesterase in human brain. J Neurosci Res 1993;35:678-89.
15. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry 1998;74:298-305.
16. Jacobs DM, Sano M, Dooneief G, et al. Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology 1995;45:957-62.
17. Growdon JH. Biomarkers of Alzheimer disease. Arch Neurol 1999;56:281-3.